United States· US:0904-7172_e3e2c3b9-806a-4639-ab44-5c5b4bb1166e
Emtricitabine and Tenofovir Disoproxil Fumarate
A nucleoside and nucleotide reverse transcriptase inhibitors product containing emtricitabine and tenofovir disoproxil fumarate, registered in United States by Major Pharmaceuticals. The same ATC class is registered in 2 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Emtricitabine and tenofovir disoproxil fumarate is registered in 2 of 19 countries.
Countries holding a registration under ATC J05AF (nucleoside and nucleotide reverse transcriptase inhibitors), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Emtricitabine and tenofovir disoproxil fumarate · ATC J05AF
2 / 19 countries
- Switzerlandprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Manufacturer
- Major Pharmaceuticals
- Country
- United States (US)
- ATC code
- J05AF
- ATC class
- Nucleoside and nucleotide reverse transcriptase inhibitors
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 3, 2026
Packs & prices · 1
- ndc11090471720730 BLISTER PACK in 1 CARTON (0904-7172-07) / 1 TABLET, FILM COATED in 1 BLISTER PACK
Regulatory notes
Same class
Other records under J05AF
Nucleoside and nucleotide reverse transcriptase inhibitors, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c8eda215-6fb6-468c-aaf7-1e83137b5e68 GET /v1/drugs/c8eda215-6fb6-468c-aaf7-1e83137b5e68?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "G70B4ETF4S",
"rxcui": "276237",
"inchikey": "XQSPYNMVSIKCOC-NTSWFWBYSA-N",
"display_name": "EMTRICITABINE",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "ORAL",
"spl_meta": {
"4feb83a5-9142-0c67-e063-6394a90a710f": {
"match": "brand_token",
"title": "EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLET, FILM COATED [NUCARE PHARMACEUTICALS, INC.]",
"spl_version": "1",
"published_date": "2026-04-22"
}
},
"productid": "0904-7172_e3e2c3b9-806a-4639-ab44-5c5b4bb1166e",
"productndc": "0904-7172",
"dosage_form": "TABLET, FILM COATED",
"orange_book": {
"appl_no": "212114",
"products": [
{
"rs": false,
"rld": false,
"te_code": "AB",
"strength": "200MG;300MG",
"product_no": "001",
"approval_date": "Jul 26, 2019"
}
],
"appl_type": "A"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE",
"proprietary_name": "Emtricitabine and Tenofovir Disoproxil Fumarate",
"active_ingred_unit": "mg/1; mg/1",
"application_number": "ANDA212114",
"marketing_category": "ANDA",
"nonproprietary_name": "Emtricitabine and Tenofovir Disoproxil Fumarate",
"start_marketing_date": "20190726",
"active_numerator_strength": "200; 300"
}See everything about emtricitabine and tenofovir disoproxil fumarate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.